Search Results
Feb 24, 2026, 11:38 ET The Dorm and the National Eating Disorders Association (NEDA) Partner on Continuing Education Event Centering Eating Disorders and Trauma
audience."For clinical professionals or dietitians registering for the workshop, they will have the opportunity to hear from Dr. Kimberly Dennis, MD, CEDS, long-time Clinical Advisory Council Member of NEDA. Together, the presentation will support professionals in learning to:Identify
More news about: The Dorm
Feb 24, 2026, 11:24 ET Solve M.E. Funds GLP-1 and Immune Target Studies to Accelerate ME/CFS and Long Covid Breakthroughs
improve symptoms and quality of life for people with ME/CFS who are receiving treatment for being overweight. The second, led by Professors Liisa Selin, MD, PhD, (Professor, Dept of Pathology, University of Massachusetts Chan Medical School), Roshan Kumar, PhD (Executive Director, Head of Translational Medicine
More news about: Solve M.E.
Feb 24, 2026, 11:00 ET Cincinnati Children's launches collaboration with MultiCare Mary Bridge Children's to elevate pediatric heart care in Pacific Northwest
live."Working together enables us to offer our expertise to kids all over the country and the world who might never come to Cincinnati," said Michael Gaies, MD, executive co-director of the Heart Institute and director of the Division of Cardiology. "We know the burden that traveling to obtain health care puts
More news about: Cincinnati Children's and Mary Bridge Children's
Feb 24, 2026, 10:58 ET Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
information provides clinicians with important evidence for patients who have historically had very limited treatment options," said Lakshmi Nayak, MD, Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute.Article Source:
More news about: USA News Group
Feb 24, 2026, 10:05 ET Orthopedic Surgeon Tobin Eckel, MD, First in Central Ohio to Use Innovative Technology for Personalized Total Ankle Replacement
multimedia:https://www.prnewswire.com/news-releases/orthopedic-surgeon-tobin-eckel-md-first-in-central-ohio-to-use-innovative-technology-for-personalized-total-ankle-replacement-302695881.htmlSOURCE
More news about: Advita Ortho, LLC
Feb 24, 2026, 10:02 ET Neurent Medical Announces Publication of Positive Randomized Controlled Trial Results for the NEUROMARK® System
with impedance controlled radiofrequency energy as an effective treatment option for patients suffering from chronic rhinitis," said Mas Takashima, MD, Principal Investigator of the trial and lead author of the publication. "The significant improvements observed across both symptom-based and quality-of-life
More news about: Neurent Medical
Feb 24, 2026, 10:00 ET DAVID DELANEY, MD, NAMED PRESIDENT OF DRUG KNOWLEDGE PROVIDER FDB (FIRST DATABANK)
NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Hearst today named David Delaney, MD, president of its
More news about: Hearst
Feb 24, 2026, 10:00 ET Kevin Schewe's "Bad Love Strikes" Wins HASTFW Screenplay Category at London Director Awards
impressive novel—and experience! Very highly recommended." Grady Harp, Amazon Top 100 Reviewer, 5-StarsAbout Kevin L. Schewe, MD, FACRO: Dr. Kevin Schewe is a board-certified cancer specialist who has been in the private practice of radiation oncology for over 39 years. Join
More news about: Dr. Kevin Schewe
Feb 24, 2026, 10:00 ET Xenocor Announces FDA Clearance of Saberscope®, the First Single-Use 5mm Articulating Laparoscope for Enhanced Surgical Visualization
hospital costs, and enhancing safety for patients and clinical staff."What stands out about the Saberscope is the reliability," said John Langell MD, Cleveland OH "Every case begins with a new scope that delivers a clear, consistent image without concerns about contamination, damage, or performance
More news about: Xenocor, Inc.
Feb 24, 2026, 09:15 ET ABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver Cancer
Duration of Response (DoR). Enrolled patients are followed for 1 year post treatment.Ammar Sarwar, MD, FSIR, Professor of Radiology, Chief of Interventional Radiology of UPMC and Andrew S. Kennedy, MD, FACRO, Physician-in-Chief of HCA Healthcare Sarah Cannon Cancer Network, serve as co-principal investigators
More news about: ABK Biomedical Inc.
Feb 24, 2026, 09:15 ET UWorld Nursing Expands Suite of NCLEX® Readiness Resources, Debuts Three-Day Comprehensive Review
engaged. "Our three-day NCLEX review was built as a high-energy, engaging alternative to the typical lecture-heavy trainings," said Chandra Pemmasani, MD, founder and CEO of UWorld. "If your nursing program needs to boost pass rates, support struggling students and provide a comprehensive final review without
More news about: UWorld
Feb 24, 2026, 09:15 ET Newport Healthcare Recognizes National Eating Disorders Awareness Week by Collaborating with Field's Top Professional Associations
and often underrecognized relationship between trauma and eating disorders. The panel featured Newport Healthcare's Medical Director Mirela Loftus, MD, PhD; National Director of Eating Disorder Programs Kara Becker, LMFT, CEDS; National Nutrition Manager Annaliese DiFabbio, RD, CEDS; and National Director
More news about: Newport Healthcare
Feb 24, 2026, 09:15 ET RDA Digital Achieves World-Class NPS
86, RDA Digital sets a new benchmark for disciplined digital and AI-enabled transformations.HUNT VALLEY, Md., Feb. 24, 2026 /PRNewswire/ -- RDA Digital (RDA) has achieved its strongest Voice of the Customer results to
More news about: RDA
Feb 24, 2026, 09:03 ET PanOxyl® Expands its Portfolio with FDA-cleared Antimicrobial Purifying Mist Powered by Hypochlorous Acid
Acid is well recognized in dermatology for its ability to reduce bacteria and calm redness without disrupting the skin barrier," said Marisa Garshick, MD. "This mist is a great option for patients who want gentle, effective purification and soothing benefits without dryness or disruption of the skin barrier."PanOxyl
More news about: Revance
Feb 24, 2026, 09:00 ET Beacon Wellness Brands Announces The 2026 plusOne Wellness Collective
Collective include:Ericka Hart, M.Ed – Sex Educator & AuthorDr. Heather Bartos, MD – OB-GYN, Menopause Expert & AuthorDr. Karyn Eilber, MD – UrogynecologistDr. Alicia Jeffrey Thomas, PT, DPT, PRPC – Pelvic Floor Physical TherapistThrough
More news about: Beacon Wellness Brands
Feb 24, 2026, 09:00 ET Cohere Health Adds Dr. Mark Leenay to Board of Directors to Advance Clinical AI Leadership and Health Plan Collaborations
health plan leadership, operational expertise, and an extensive clinical and academic background. He previously served as COO of ChenMed, CEO of InHealth MD Alliance, and EVP and Chief Medical Officer of WellCare Health Plans, and spent a decade in executive leadership positions at UnitedHealth Group. He
More news about: Cohere Health
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. 177Lu-BetaBart is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. 177Lu-BetaBart is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma liefert erste Patientendosis in Phase 1/2a der klinischen Studie von Radiopharm Theranostics mit 177Lu-BetaBart (RV-01)
(RV-01)RV-01 ist das erste radiopharmazeutische Therapeutikum, das von Radiopharm Ventures, dem Joint Venture zwischen Radiopharm Theranostics und dem MD Anderson Cancer Center der Universität von Texas, entwickelt wurde. 177Lu-BetaBart ist ein mit 177Lutetium konjugiertes Therapeutikum, das auf B7-H3
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma suministra la primera dosis en el estudio clínico de Radiopharm Theranostics
terapéutico radiofarmacéutico desarrollado por Radiopharm Ventures, la empresa conjunta formada entre Radiopharm Theranostics y el Centro Oncológico MD Anderson de la Universidad de Texas. 177Lu-BetaBart es un agente terapéutico conjugado con 177Lutecio que actúa sobre B7-H3, una molécula de punto de
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma fournit la première dose à un patient dans le cadre de l'étude clinique de phase 1/2a de Radiopharm Theranostics sur le 177Lu-BetaBart (RV-01)
(RV-01)RV-01 est le premier agent thérapeutique radiopharmaceutique développé par Radiopharm Ventures, la coentreprise formée par Radiopharm Theranostics et le MD Anderson Cancer Center de l'Université du Texas. 177Lu-BetaBart est un agent thérapeutique conjugué au lutécium qui cible B7-H3, une molécule de contrôle
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 08:55 ET Healthy Leaders Build Stronger Businesses: EO Baltimore Hosts "Happy Healthy Human" Luncheon for Entrepreneurs March 11
peer network built specifically for founders — where business growth and personal growth ALIGN.March 11, 2026Baltimore, MD
More news about: Entrepreneurs' Organization of Baltimore
Feb 24, 2026, 08:55 ET New National Agenda Paves the Way for Improved Parkinson's Care
ensure that people with Parkinson's receive the support they need to live well," said Chief Medical Officer of the Parkinson's Foundation, Sneha Mantri, MD, MS, FAAN.The four priorities were achieved through consensus and address the most pressing challenges in PD care. Their corresponding solutions
More news about: Parkinson's Foundation
Feb 24, 2026, 08:42 ET New Kiddie Academy® of Fleming Island focuses on whole family
inception in 1981, the Kiddie Academy system has been recognized as a leading brand in educational child care. The company, headquartered in Abingdon, Md., serves families and their children ages 6 weeks to 12 years old, offering full- and part-time care, before- and after-school care, and summer camp programs,
More news about: Kiddie Academy
Feb 24, 2026, 08:00 ET Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
our clinical footprint to include MD Anderson Cancer Center, a world-renowned institution, is a significant milestone for the ATR-04 program," said Francisco Salva, CEO of Azitra. "As a leading cancer site that treats thousands of patients a year, oncologists at MD Anderson understand the impact of EGFRi-associated
More news about: Azitra, Inc.